CompletedPhase 2NCT03294161

Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital Universitário Professor Edgard Santos
Principal Investigator
Edgar M Carvalho, MD, PhD
Federal University of Bahia
Intervention
Immucillin DI4G(drug)
Enrollment
50 enrolled
Eligibility
18-65 years · All sexes
Timeline
2014 – 2017

Study locations (1)

Collaborators

Conselho Nacional de Desenvolvimento Científico e Tecnológico · Federal University of Bahia · Pontificia Universidade Católica do Rio Grande do Sul

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03294161 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials